Previous studies in animals have found that high doses of CPF, which inhibits plasma butyryl cholinesterase and brain acetylcholinesterase activity, can promote obesity and glucose dysregulation through mechanisms that are poorly defined but may involve increases in energy intake and/or alterations in the gut microbiome34–39. Here, BCHE is linked to obesity due to melanocortin 4 receptor deficiency.